The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2025 | Prospective inhalation therapy against advanced lung cancer
Wen Wee Ma, MBBS, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, shares insight into inhaled KB707, a novel HSV-based immunotherapy against lung cancer and solid tumours affecting the lung. Local delivery with breathing allows for high treatment level without systemic side effects, a major drawback of current chemotherapy and immunotherapies. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So I think there’s great potential with this because most of the, almost all of the chemotherapy or immunotherapy currently is given IV or oral with systemic exposure. So with local delivery such as by breathing, we can deliver a large high level of treatment to the lung without really causing systemic side effects. So I think this has a lot of potential in lung cancer patients and also solid tumor or solid tumor diseases that affect the lung...
So I think there’s great potential with this because most of the, almost all of the chemotherapy or immunotherapy currently is given IV or oral with systemic exposure. So with local delivery such as by breathing, we can deliver a large high level of treatment to the lung without really causing systemic side effects. So I think this has a lot of potential in lung cancer patients and also solid tumor or solid tumor diseases that affect the lung. And particularly there’s also situations such as breast cancer that get lymphogenic spread where patients have shortness of breath. So this has a potential application for that group of patients as well.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
